Human Ovarian Cancer Peripheral Blood Mononuclear Cells

Description

Human Ovarian Cancer Peripheral Blood Mononuclear Cells (PBMCs) are isolated from patients with epithelial ovarian cancer and consist of lymphocytes (T cells, B cells, NK cells) and monocytes that exhibit tumor-induced immune dysfunction. These cells demonstrate compromised antitumor activity, including impaired cytotoxic CD8⁺ T cell and NK cell function, along with expansion of immunosuppressive populations such as regulatory T cells (Tregs) and monocyte-derived myeloid-derived suppressor cells (MDSCs). The PBMC compartment in ovarian cancer patients frequently shows upregulated immune checkpoint molecules (PD-1, CTLA-4, TIM-3) and altered cytokine profiles (elevated IL-10, TGF-β), contributing to immune evasion. These cells serve as a valuable model for studying tumor immunosuppression mechanisms, identifying prognostic immune signatures, and developing immunotherapeutic strategies to reverse T cell exhaustion and enhance antitumor immunity in ovarian cancer. These PBMCs provide a platform for advancing ovarian cancer immunotherapy, integrating genomics PBMC ovarian cancer analyses, enabling comprehensive PBMC characterization cancer, revealing insights into PBMC metabolism ovarian cancer, and guiding emerging ovarian cancer research trends.